AAPL321.20-7.02 (-2.14%) ▼|ABBV256.86-3.35 (-1.29%) ▼|ABT109.40+0.61 (+0.56%) ▲|ACN188.41-4.71 (-2.44%) ▼|ADBE268.36-17.40 (-6.09%) ▼|AMAT452.33+16.42 (+3.77%) ▲|AMD474.25+18.09 (+3.97%) ▲|AMGN436.50-7.62 (-1.72%) ▼|AMT176.21-1.54 (-0.87%) ▼|AMZN257.12-1.79 (-0.69%) ▼|AVGO354.76-2.40 (-0.67%) ▼|AXP327.37-2.45 (-0.74%) ▼|BA210.35-0.17 (-0.08%) ▼|BAC62.69-0.04 (-0.06%) ▼|BKNG193.83-1.30 (-0.67%) ▼|BLK1,121.01-5.14 (-0.46%) ▼|BMY66.66-1.44 (-2.11%) ▼|BNY165.49+1.16 (+0.71%) ▲|BRK-B506.14-1.99 (-0.39%) ▼|C137.88-0.26 (-0.19%) ▼|CAT810.38+10.24 (+1.28%) ▲|CL89.25-0.84 (-0.93%) ▼|CMCSA26.57-0.09 (-0.32%) ▼|COF219.98-0.53 (-0.24%) ▼|COP134.84-0.88 (-0.65%) ▼|COST917.18-8.23 (-0.89%) ▼|CRM260.81-3.62 (-1.37%) ▼|CSCO109.41+0.80 (+0.74%) ▲|CVS97.30+0.10 (+0.10%) ▲|CVX209.04-2.28 (-1.08%) ▼|DE696.31+1.90 (+0.27%) ▲|DHR206.74-4.30 (-2.04%) ▼|DIS105.69-1.48 (-1.38%) ▼|DUK120.43-0.97 (-0.80%) ▼|EMR153.27+3.06 (+2.04%) ▲|FDX321.74-2.58 (-0.79%) ▼|GD359.50-6.38 (-1.74%) ▼|GE335.57+2.09 (+0.63%) ▲|GEV941.37-0.48 (-0.05%) ▼|GILD150.61-0.61 (-0.40%) ▼|GM87.16+0.12 (+0.14%) ▲|GOOG335.28-3.80 (-1.12%) ▼|GOOGL338.62-3.64 (-1.06%) ▼|GS1,036.81-1.12 (-0.11%) ▼|HD320.54+2.47 (+0.78%) ▲|HON208.02+0.39 (+0.19%) ▲|IBM234.97+0.26 (+0.11%) ▲|INTC94.88+3.21 (+3.50%) ▲|INTU332.99-11.32 (-3.29%) ▼|ISRG364.16-5.67 (-1.53%) ▼|JNJ275.91-2.52 (-0.91%) ▼|JPM358.61-3.45 (-0.95%) ▼|KO88.01-0.81 (-0.91%) ▼|LIN479.26-2.93 (-0.61%) ▼|LLY1,144.43-15.17 (-1.31%) ▼|LMT526.07-6.88 (-1.29%) ▼|LOW203.87+1.97 (+0.97%) ▲|LRCX303.24+10.58 (+3.61%) ▲|MA582.37-3.34 (-0.57%) ▼|MCD256.84-2.80 (-1.08%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.37+1.27 (+1.36%) ▲|META609.53-1.15 (-0.19%) ▼|MMM168.25-0.07 (-0.04%) ▼|MO68.83-0.67 (-0.96%) ▼|MRK150.36-1.99 (-1.30%) ▼|MS217.09-0.06 (-0.03%) ▼|MSFT501.03-9.10 (-1.78%) ▼|MU1,000.66+42.50 (+4.44%) ▲|NEE83.46-0.61 (-0.72%) ▼|NFLX78.97-3.71 (-4.48%) ▼|NKE38.38-0.39 (-1.01%) ▼|NOW141.53-4.06 (-2.79%) ▼|NVDA230.82+2.37 (+1.04%) ▲|ORCL157.65+3.61 (+2.34%) ▲|PEP137.75-0.79 (-0.57%) ▼|PFE28.51-0.30 (-1.04%) ▼|PG146.43-0.49 (-0.33%) ▼|PLTR174.57-7.96 (-4.36%) ▼|PM182.70-3.47 (-1.86%) ▼|QCOM167.91-0.66 (-0.39%) ▼|RTX200.36-1.78 (-0.88%) ▼|SBUX105.60-0.22 (-0.21%) ▼|SCHW109.23-1.15 (-1.04%) ▼|SO87.96-0.81 (-0.91%) ▼|SPG210.99-0.54 (-0.25%) ▼|T25.93-0.27 (-1.01%) ▼|TMO612.73-5.70 (-0.92%) ▼|TMUS182.20-5.82 (-3.10%) ▼|TSLA352.45-23.92 (-6.35%) ▼|TXN257.92+4.09 (+1.61%) ▲|UBER76.08+0.12 (+0.16%) ▲|UNH397.52-3.42 (-0.85%) ▼|UNP290.61+1.46 (+0.50%) ▲|UPS102.70-0.80 (-0.77%) ▼|USB63.56+0.03 (+0.05%) ▲|V375.95-2.80 (-0.74%) ▼|VZ50.30-0.29 (-0.57%) ▼|WFC89.72+0.53 (+0.59%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM160.45-1.76 (-1.09%) ▼|AAPL321.20-7.02 (-2.14%) ▼|ABBV256.86-3.35 (-1.29%) ▼|ABT109.40+0.61 (+0.56%) ▲|ACN188.41-4.71 (-2.44%) ▼|ADBE268.36-17.40 (-6.09%) ▼|AMAT452.33+16.42 (+3.77%) ▲|AMD474.25+18.09 (+3.97%) ▲|AMGN436.50-7.62 (-1.72%) ▼|AMT176.21-1.54 (-0.87%) ▼|AMZN257.12-1.79 (-0.69%) ▼|AVGO354.76-2.40 (-0.67%) ▼|AXP327.37-2.45 (-0.74%) ▼|BA210.35-0.17 (-0.08%) ▼|BAC62.69-0.04 (-0.06%) ▼|BKNG193.83-1.30 (-0.67%) ▼|BLK1,121.01-5.14 (-0.46%) ▼|BMY66.66-1.44 (-2.11%) ▼|BNY165.49+1.16 (+0.71%) ▲|BRK-B506.14-1.99 (-0.39%) ▼|C137.88-0.26 (-0.19%) ▼|CAT810.38+10.24 (+1.28%) ▲|CL89.25-0.84 (-0.93%) ▼|CMCSA26.57-0.09 (-0.32%) ▼|COF219.98-0.53 (-0.24%) ▼|COP134.84-0.88 (-0.65%) ▼|COST917.18-8.23 (-0.89%) ▼|CRM260.81-3.62 (-1.37%) ▼|CSCO109.41+0.80 (+0.74%) ▲|CVS97.30+0.10 (+0.10%) ▲|CVX209.04-2.28 (-1.08%) ▼|DE696.31+1.90 (+0.27%) ▲|DHR206.74-4.30 (-2.04%) ▼|DIS105.69-1.48 (-1.38%) ▼|DUK120.43-0.97 (-0.80%) ▼|EMR153.27+3.06 (+2.04%) ▲|FDX321.74-2.58 (-0.79%) ▼|GD359.50-6.38 (-1.74%) ▼|GE335.57+2.09 (+0.63%) ▲|GEV941.37-0.48 (-0.05%) ▼|GILD150.61-0.61 (-0.40%) ▼|GM87.16+0.12 (+0.14%) ▲|GOOG335.28-3.80 (-1.12%) ▼|GOOGL338.62-3.64 (-1.06%) ▼|GS1,036.81-1.12 (-0.11%) ▼|HD320.54+2.47 (+0.78%) ▲|HON208.02+0.39 (+0.19%) ▲|IBM234.97+0.26 (+0.11%) ▲|INTC94.88+3.21 (+3.50%) ▲|INTU332.99-11.32 (-3.29%) ▼|ISRG364.16-5.67 (-1.53%) ▼|JNJ275.91-2.52 (-0.91%) ▼|JPM358.61-3.45 (-0.95%) ▼|KO88.01-0.81 (-0.91%) ▼|LIN479.26-2.93 (-0.61%) ▼|LLY1,144.43-15.17 (-1.31%) ▼|LMT526.07-6.88 (-1.29%) ▼|LOW203.87+1.97 (+0.97%) ▲|LRCX303.24+10.58 (+3.61%) ▲|MA582.37-3.34 (-0.57%) ▼|MCD256.84-2.80 (-1.08%) ▼|MDLZ61.48+0.03 (+0.04%) ▲|MDT94.37+1.27 (+1.36%) ▲|META609.53-1.15 (-0.19%) ▼|MMM168.25-0.07 (-0.04%) ▼|MO68.83-0.67 (-0.96%) ▼|MRK150.36-1.99 (-1.30%) ▼|MS217.09-0.06 (-0.03%) ▼|MSFT501.03-9.10 (-1.78%) ▼|MU1,000.66+42.50 (+4.44%) ▲|NEE83.46-0.61 (-0.72%) ▼|NFLX78.97-3.71 (-4.48%) ▼|NKE38.38-0.39 (-1.01%) ▼|NOW141.53-4.06 (-2.79%) ▼|NVDA230.82+2.37 (+1.04%) ▲|ORCL157.65+3.61 (+2.34%) ▲|PEP137.75-0.79 (-0.57%) ▼|PFE28.51-0.30 (-1.04%) ▼|PG146.43-0.49 (-0.33%) ▼|PLTR174.57-7.96 (-4.36%) ▼|PM182.70-3.47 (-1.86%) ▼|QCOM167.91-0.66 (-0.39%) ▼|RTX200.36-1.78 (-0.88%) ▼|SBUX105.60-0.22 (-0.21%) ▼|SCHW109.23-1.15 (-1.04%) ▼|SO87.96-0.81 (-0.91%) ▼|SPG210.99-0.54 (-0.25%) ▼|T25.93-0.27 (-1.01%) ▼|TMO612.73-5.70 (-0.92%) ▼|TMUS182.20-5.82 (-3.10%) ▼|TSLA352.45-23.92 (-6.35%) ▼|TXN257.92+4.09 (+1.61%) ▲|UBER76.08+0.12 (+0.16%) ▲|UNH397.52-3.42 (-0.85%) ▼|UNP290.61+1.46 (+0.50%) ▲|UPS102.70-0.80 (-0.77%) ▼|USB63.56+0.03 (+0.05%) ▲|V375.95-2.80 (-0.74%) ▼|VZ50.30-0.29 (-0.57%) ▼|WFC89.72+0.53 (+0.59%) ▲|WMT107.32-1.10 (-1.01%) ▼|XOM160.45-1.76 (-1.09%) ▼|
28.3 C
New York
Friday, September 4, 2026

Tag: toxicity

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for...

Azitra, Inc. Announces Reverse Stock Split

Common Stock Will Begin Trading on a Split-Adjusted Basis on August 21, 2025 BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a...

Booking Health Unveils New Study: Role of Immunotherapy in Extending Life Expectancy for Stage4 Cervical Cancer Patients

Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients. The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments.

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in...

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.

Global Flame Retardant Chemicals Market Accelerates in Response to Rising Fire Safety Standards | ‘BCC Research LLC’

"With rising fire safety standards and the growing use of electric vehicles, demand for flame retardant chemicals is expanding across industries such as construction,...

Global Flame Retardant Chemicals Market Accelerates in Response to Rising Fire Safety Standards | ‘BCC Research LLC’

"With rising fire safety standards and the growing use of electric vehicles, demand for flame retardant chemicals is expanding across industries such as construction,...

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an...

Cell Line and Membrane Market to Grow at 12.5% CAGR Through 2030

"Market Analysis Highlights Growth Potential, Emerging Technologies, ESG Trends, and Strategic Insights in the Cell Line and Membrane Sector" BOSTON, Aug. 5, 2025 /PRNewswire/ --...

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

         - Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis -

MDLifespan and Dr. Jill Carnahan Launch “Next Gen Mold Detox” Using Therapeutic Plasma Exchange

Dr Jill's MDLifespan Mold Protocol is the First Clinically Proven Therapeutic Plasma Exchange Detox to Remove up to 90% of Mold Toxins DENVER, Aug. 4,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsToxicity